InMed Pharmaceuticals (INM) Equity Ratio: 2021-2025
Historic Equity Ratio for InMed Pharmaceuticals (INM) over the last 4 years, with Sep 2025 value amounting to 0.87.
- InMed Pharmaceuticals' Equity Ratio rose 8.13% to 0.87 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.87, marking a year-over-year increase of 8.13%. This contributed to the annual value of 0.86 for FY2025, which is 10.74% up from last year.
- Per InMed Pharmaceuticals' latest filing, its Equity Ratio stood at 0.87 for Q3 2025, which was up 0.60% from 0.86 recorded in Q2 2025.
- InMed Pharmaceuticals' Equity Ratio's 5-year high stood at 0.88 during Q3 2021, with a 5-year trough of -0.88 in Q3 2023.
- Its 3-year average for Equity Ratio is 0.66, with a median of 0.83 in 2024.
- As far as peak fluctuations go, InMed Pharmaceuticals' Equity Ratio tumbled by 216.24% in 2023, and later surged by 191.44% in 2024.
- Quarterly analysis of 5 years shows InMed Pharmaceuticals' Equity Ratio stood at 0.73 in 2021, then rose by 15.92% to 0.85 in 2022, then decreased by 1.18% to 0.84 in 2023, then decreased by 13.15% to 0.73 in 2024, then increased by 8.13% to 0.87 in 2025.
- Its Equity Ratio stands at 0.87 for Q3 2025, versus 0.86 for Q2 2025 and 0.76 for Q1 2025.